Amphastar Pharmaceuticals Reaches New 52-Week High at $12.18 (AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) hit a new 52-week high on Tuesday , AR Network reports. The company traded as high as $12.18 and last traded at $11.36, with a volume of 110,514 shares changing hands. The stock had previously closed at $11.46.
AMPH has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.
The stock has a 50-day moving average of $9.52 and a 200-day moving average of $9.53. The company’s market cap is $513.4 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.17 EPS for the current fiscal year.
In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff bought 3,500 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, August 19th. The shares were purchased at an average cost of $10.00 per share, with a total value of $35,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.